Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Quercetin Inhibits Ferroptosis to Mitigate Liver Injury in W

    2026-05-12

    Quercetin as a Ferroptosis Modulator in Wilson’s Disease: Mechanistic Insights from Recent Research

    Study Background and Research Question

    Wilson’s disease (WD) is a rare, inherited disorder of copper metabolism, marked by excessive hepatic copper accumulation and progressive liver damage. While the primary genetic driver is ATP7B dysfunction, the downstream mechanisms of copper-induced hepatotoxicity remain incompletely characterized. Ferroptosis—an iron-dependent form of regulated cell death involving lipid peroxidation—has emerged as a candidate pathway in WD pathology, but its therapeutic modulation is largely unexplored. The study by Zhao et al. addresses whether quercetin, a dietary flavonoid and known PI3K inhibitor, can alleviate WD-associated liver injury by intervening in the ferroptosis pathway (paper).

    Key Innovation from the Reference Study

    The central innovation of this work lies in the mechanistic elucidation of quercetin’s protective role against ferroptosis-driven liver injury. Specifically, the authors reveal that quercetin directly binds to and inhibits acyl-CoA synthetase long-chain family member 4 (ACSL4), thereby suppressing the ACSL4/LPCAT3/ALOX15 signaling cascade critical for phospholipid peroxidation—a hallmark of ferroptosis. This expands the therapeutic profile of quercetin beyond its established activities as a PI3K inhibitor, anti-inflammatory agent, and apoptosis inducer (paper).

    Methods and Experimental Design Insights

    Zhao et al. employed both in vivo and in vitro WD models:
    • Animal models: Atp7btx-J/J mice, genetically predisposed to copper accumulation, were treated with quercetin.
    • Cellular models: HepG2 hepatocellular carcinoma cells were used to dissect molecular mechanisms.
    Key assays included:
    • Histopathology and transmission electron microscopy for structural liver assessment.
    • Serum biochemistry for liver function markers.
    • Iron content and lipid peroxidation markers (malondialdehyde, MDA).
    • Glutathione metabolism and mitochondrial membrane potential (JC-1 probe) to assess redox status and organelle integrity.
    • Lipidomics to profile glycerolipid and phospholipid composition.
    • Mechanistic assays: ACSL4 overexpression, molecular docking, molecular dynamics, cellular thermal shift, surface plasmon resonance, RT-qPCR, Western blot, and immunofluorescence (paper).

    Core Findings and Why They Matter

    Quercetin administration led to several key outcomes:
    • Reduction of hepatic injury: Marked improvements in histopathology and serum markers signaled mitigated liver damage (source: paper).
    • Suppression of ferroptosis: Quercetin decreased iron overload, lipid peroxidation, and restored mitochondrial membrane potential, consistent with ferroptosis inhibition (source: paper).
    • Lipid homeostasis restoration: Lipidomics revealed that aberrant accumulation of glycerolipids was reversed, and glycerophospholipid metabolism was normalized, indicating a blockade of ferroptotic lipid remodeling (source: paper).
    • Direct ACSL4 targeting: Mechanistic experiments confirmed quercetin’s direct binding and inhibition of ACSL4, validated by biophysical and molecular assays (source: paper).
    • Antioxidant defense restoration: Quercetin improved glutathione levels and superoxide dismutase activity, further supporting its role as an anti-inflammatory agent and redox modulator (source: paper).
    Together, these data position quercetin as a multi-target modulator capable of interrupting the iron-lipid-peroxidation axis central to WD progression.

    Protocol Parameters

    • ferroptosis inhibition assay | JC-1 probe, MDA quantification, iron content (μg/g tissue) | WD mouse and hepatocyte models | Direct assessment of mitochondrial integrity and lipid peroxidation | paper
    • lipidomics | high-resolution mass spectrometry | liver homogenates | Detects metabolic shifts in phospholipid and glycerolipid pools | paper
    • ACSL4 binding | surface plasmon resonance, cellular thermal shift | recombinant protein and cell lysate | Validates molecular interaction and target engagement | paper
    • apoptosis assessment | caspase 3/8/9 activity (U/mg protein) | HepG2 cells | Dissects interplay between apoptosis and ferroptosis | workflow_recommendation
    • PI3K pathway modulation | phospho-Akt/ERK Western blot | hepatocyte or cancer models | Explores intersection with quercetin’s secondary mechanisms | workflow_recommendation

    Comparison with Existing Internal Articles

    Several recent reviews and mechanistic explorations from internal resources reinforce and contextualize these findings: By integrating mechanistic evidence from different domains—ferroptosis, PI3K inhibition, and apoptosis modulation—these resources enable researchers to develop comprehensive, multi-modal experimental designs.

    Limitations and Transferability

    While the study offers strong preclinical evidence, several limitations warrant attention:
    • Model specificity: Findings are derived from murine and hepatocyte models, which may not fully recapitulate human WD pathophysiology (source: paper).
    • Dosing and pharmacokinetics: The effective concentrations and delivery routes for quercetin in humans remain to be optimized (workflow_recommendation).
    • Off-target effects: Given quercetin’s multi-target nature (e.g., PI3K and NF-κB inhibition), disentangling its ferroptosis-specific actions from broader cytoprotective effects will require further investigation (source: internal_article).
    • Translational readiness: Clinical validation is needed to confirm if the observed molecular effects translate to meaningful patient outcomes in WD or related hepatic disorders (workflow_recommendation).

    Why this cross-domain matters, maturity, and limitations

    The intersection of ferroptosis research with established cancer and inflammation pathways—where quercetin is already widely studied—underscores the value of leveraging this molecule for multi-faceted experimental designs. However, while cross-domain mechanistic parallels are promising, direct clinical translation between hepatic and oncologic contexts should proceed cautiously and be anchored in robust, context-specific validation (source: internal_article).

    Research Support Resources

    For researchers aiming to reproduce or extend these workflows, high-purity quercetin (SKU N1841) is available from APExBIO (product). This compound supports applications in cell signaling, ferroptosis, and apoptosis assays, and its physicochemical properties are well-documented for experimental planning. As always, it is recommended to confirm batch-specific solubility and purity parameters for sensitive protocols. This reagent is intended for scientific research use only.